Surfactant protein D attenuates sub-epithelial fibrosis in allergic airways disease through TGF-β

Hirohisa Ogawa1,2,4, Julie G Ledford1,2, Sambuddho Mukherjee1,2, Yoshinori Aono3, Yasuhiko Nishioka3, James J Lee5, Keisuke Izumi4 and John W Hollingsworth2,6,7*

Abstract

Background: Surfactant protein D (SP-D) can regulate both innate and adaptive immunity. Recently, SP-D has been shown to contribute to the pathogenesis of airway allergic inflammation and bleomycin-induced pulmonary fibrosis. However, in allergic airways disease, the role of SP-D in airway remodeling remains unknown. The objective of this study was to determine the contribution of functional SP-D in regulating sub-epithelial fibrosis in a mouse chronic house dust mite model of allergic airways disease.

Methods: C57BL/6 wild-type (WT) and SP-D−/− mice (C57BL/6 background) were chronically challenged with house dust mite antigen (Dermatophagoides pteronyssinus, Dp). Studies with SP-D rescue and neutralization of TGF-β were conducted. Lung histopathology and the concentrations of collagen, growth factors, and cytokines present in the airspace and lung tissue were determined. Cultured eosinophils were stimulated by Dp in presence or absence of SP-D.

Results: Dp-challenged SP-D−/− mice demonstrate increased sub-epithelial fibrosis, collagen production, eosinophil infiltration, TGF-β1, and IL-13 production, when compared to Dp-challenged WT mice. By immunohistology, we detected an increase in TGF-β1 and IL-13 positive eosinophils in SP-D−/− mice. Purified eosinophils stimulated with Dp produced TGF-β1 and IL-13, which was prevented by co-incubation with SP-D. Additionally, treatment of Dp challenged SP-D−/− mice with exogenous SP-D was able to rescue the phenotypes observed in SP-D−/− mice and neutralization of TGF-β1 reduced sub-epithelial fibrosis in Dp-challenged SP-D−/− mice.

Conclusion: These data support a protective role for SP-D in the pathogenesis of sub-epithelial fibrosis in a mouse model of allergic inflammation through regulation of eosinophil-derived TGF-β.

Keywords: Surfactant protein D, Asthma, Fibrosis, Airway remodeling, Eosinophil, Transforming growth factor beta

Background

Surfactant is a lipoprotein complex that resides at the air-liquid interface of the lungs and is most commonly known for its role in reducing surface tension. Surfactant is produced by alveolar type II cells and airway Clara cells [1] and is composed of approximately 10% proteins, which includes surfactant protein (SP)-A, SP-B, SP-C and SP-D. SP-A and SP-D are members of collectin family of proteins and can modulate innate immunity. Previous reports have shown that SP-D can enhanced pulmonary clearance of pathogens including: Pseudomonas aerginosa [2], Klebsiella pneumonia [3], respiratory syncytial virus (RSV) [4] and Influenza virus [5]. Furthermore, SP-D has also been shown to modify allergic responses in the lungs and can bind to several common allergens, including house dust mite (Dermatophagoides pteronyssinus, Dp) [6], Aspergillus fumigatus, (Af) [7] and pollen granules [8]. Additionally SP-D reduce airway hyperresponsiveness (AHR) and eosinophilia in either ovalbumin (OVA) [9] or in Af [10] murine models of allergic airways disease and SP-D administration after antigen challenge can attenuate eosinophilia and Th2 cytokine production in Dp-sensitized mice [11-13]. While SP-D can attenuate AHR and eosinophilia in these allergic models, the role of SP-D in remodeling of the airways remains unexplored.

Airway remodeling is central to the pathogenesis of asthma and can include sub-epithelial fibrosis, mucus
cell hyperplasia and smooth muscle hypertrophy/hyperplasia. A better understanding of the factors that regulate the pathogenesis of sub-epithelial fibrosis may provide an opportunity for novel interventions in chronic bronchial asthma. Previous work demonstrated that both SP-A and SP-D can mitigate pulmonary fibrosis in mouse models of lung injury. For example, SP-A-deficient and SP-D-deficient mice are susceptible to bleomycin-induced lung injury and display increased cellular inflammation, more severe lung fibrosis, and reduced survival [14,15]. Studies using the bleomycin lung fibrosis model support that SP-D attenuate pulmonary fibrosis through both regulation of TGF-β1 and PDGF-AA production, as well as, limiting fibrocyte migration into the lung [16]. Clinical relevance of these findings is supported by the association between serum levels of either SP-A or SP-D and mortality in patients with pulmonary fibrosis [17,18].

Based on these previous observations, we used a model of chronic exposure to Dp to test the hypothesis that SP-D would attenuate the development of sub-epithelial fibrosis in an allergic airways disease. Present findings here suggest that SP-D plays a protective role in allergic airways by reducing the development of sub-epithelial fibrosis.

Materials and methods
Detailed methods are described in the supporting information.

Preparation of antigen
House-dust mite antigen (Dermatophagoides pteronyssinus, Dp) was purchased from Cosmobio Ltd (Tokyo, Japan). Endotoxin levels were reduced using endotoxin removal solution (Sigma-Aldrich, Japan) to <0.02 EU/mg.

Animal protocol
All mouse studies were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Institute of Animal Care and Use Committee (IACUC) at Duke University. All surgery was performed under Ketamine (50 mg/kg)/Xylazine (5 mg/kg) anesthesia and all efforts were made to minimize suffering.

SP-D knockout (SP-D−/−) mice (C57BL/6 background) and IL-5 transgenic mice (C57BL/6 background) were generated as previously described [19,20]. Wild-type (WT) C57BL/6 mice were purchased from The Jackson Laboratory and bred in-house to control for environmental conditions. 6–10 week old mice were sensitized and challenged by Dp as described previously [21] (Figure 1). 3–5 mice per group were used in each experiment and these experiments were repeated for 2–3 times. Data from experiments were pooled for analysis. Bronchoalveolar lavage (BAL) was performed and lungs were harvested for histopathology and lung homogenization [21].

Figure 1 Experimental mouse protocols. (A) Model of sensitization and chronic challenge to Dp (B) SP-D rescue model (C) Anti-TGF-β1 antibody treatment model.
Exenatide SP-D administration in vivo
Recombinant SP-D was isolated from Chinese hamster ovary cells expressing rat SP-D protein as described previously [22]. Recombinant SP-D (3 μg in 50 μl PBS) or 50 μl PBS as control was administered into DP-challenged SP-D−/− mouse by oropharyngeal aspiration as described previously [15,16] twice weekly from days 13 to 38 (Figure 1).

Anti-TGF-β1 antibody administration in vivo
1.0 mg/kg of Anti-TGF-β1 antibody (R&D Systems, Minneapolis, MN) or 1.0 mg/kg of IgG isotype antibody (R&D Systems) as control was administered intraperitoneally into Dp-challenged WT and SP-D−/− mouse twice weekly from days 14 to 37 (Figure 1).

Eosinophil purification and in vitro experiment
Eosinophils were purified from blood of IL-5 transgenic mouse as described previously and purity was determined to be greater than 95% [23]. Eosinophils (4×10^5) were incubated in 48 well plates in the presence or absence of SP-D for 1 hr. After pre-incubation, eosinophils were stimulated by various concentration of Dp solution for 24 hrs. SP-D was boiled by 100°C for 10 min and was used as heat-inactivated SP-D [24].

Histology
Lung tissue was fixed in 10% formalin and embedded in paraffin. Three-micrometer thick sequential sections were performed. Sections for fibrosis were stained with Gomori’s trichrome stain. Sequential sections were stained with Luna-modified stain and TGF-β1 and IL-13 immunohistochemistry (IHC). Both primary antibodies were purchased from Abcam (Cambridge, UK). IHC were performed as described previously [25]. Morphological analysis was performed quantitatively by Image J (National Institutes of Health).

Measurements of total protein and cytokine concentrations
Harvested lungs were homogenized in lysis buffer (Cell Signaling Technology, Inc. Danvers, MA) containing 1 mM phenylmethanesulfonyl fluoride (PMSF, Sigma-Aldrich) using Savant FastPrep FP120 Homogenizer (Thermo Scientific, Waltham, MA). Protein concentrations were determined by the BCA method (Pierce, Rockford, IL). Cytokines/growth factor were measured with commercial ELISA kits (details were described in Additional file 1). The values graphed for cytokine were adjusted to the total protein concentration of the respective lung samples.

Collagen assay
Lungs were homogenized in 0.5 M acetic acid (50 volumes to wet lung weight) containing about 1 mg/ml pepsin (Sigma) using Savant FastPrep FP120 Homogenizer (Thermo Scientific, Waltham, MA). Total lung collagen was determined using the Sircol Collagen Assay kit (Biocolor Ltd., Belfast, Northern Ireland) according to the manufacturer’s instructions. The values graphed for collagen were adjusted to the total protein concentration of the respective lung samples.

Flow cytometry
The lungs were minced and enzymatically digested (DNAse and Collagenase) for 1 hr at 37°C. Cells were stained by various fluorescence conjugated -antibodies (details were described in Additional file 1). The stained cells were analyzed by FACS using a BD LSRII and BD FACS Canto II (San Diego, CA) for acquisition.

Statistical analysis
Comparisons between groups were analyzed using one-way ANOVA with post-hoc Tukeys analysis. Some comparisons between groups made with Student T-test without ANOVA (GraphPad Prism, version 5.0; GraphPad Software, Inc., San Diego, CA). Data are presented as mean ± SEM. Differences were considered statistically significant if p values were less than 0.05.

Results
Sub-epithelial airway fibrosis in Dp challenged mice
Chronic Dp exposure increased sub-epithelial fibrosis in Dp-challenged WT and SP-D−/− mice compared to PBS challenged mice (Figure 2A). When compared with Dp-challenged WT mice, Dp-challenged SP-D−/− mice demonstrate markedly increased sub-epithelial fibrosis after chronic exposure (Figure 2A). The thickness of sub-epithelial fibrosis was increased in all Dp-challenged groups when compared to PBS challenged groups. However, the thickness of sub-epithelial fibrosis of Dp challenged SP-D−/− mice was significantly greater than that of Dp-challenged WT mice (Figure 2B). Likewise, the amount of collagen in the lungs of Dp-challenged SP-D−/− mice was significantly increased compared to the lungs of Dp-challenged WT mice and PBS-challenged SP-D−/− mice (Figure 2C).

Cellular inflammation in Dp-challenged mice
Differential cell counts from the bronchial alveolar lavage fluid (BALF) and cytokine/growth factor concentrations in BALF and whole lungs were examined to evaluate the allergic inflammation of Dp-challenged mice. Although there were no observed differences in the number of lymphocytes in BALF among both groups of Dp-challenged mice, the total cells, eosinophils, and
Figure 2 Sub-epithelial airway fibrosis in SP-D−/− mice after Dp chronic exposure. (A) Representative photomicrographs of lungs from either wild-type (WT) C57BL/6 mice or SP-D−/− mice stained with Gomori’s trichrome on day 42 after PBS or Dp challenge. Vertical rows were arranged by group and horizontal rows were results representative of 3 independent experiments. Magnification: 100x. Scale bar = 200 μm. Dp/PBS: Dp sensitized and PBS challenged mice. Dp/Dp: Dp sensitized and Dp challenged mice. (B) Morphological analysis of sub-epithelial fibrosis. (C) Collagen content in the lungs of SP-D−/− mice or C57BL/6 (WT) mice on day 42 after saline or Dp challenge. Subepithelial fibrosis thickness and collagen production was measured as described in Material and Methods. Data are presented as means ± SEM obtained from 3 different experiments. 3–5 mice per group were used in each experiment (N = 10–15). White bars: PBS-challenged mice in each group. Black bar: Dp-challenged WT mice. Shaded bar: Dp-challenged SP-D−/− mice. *p < 0.05.

Figure 3 BAL fluid cell analysis and cytokine concentration in Dp-challenged SP-D−/− mice. (A) Bronchoalveolar lavage (BAL) was performed for total cell count and differentials. (B) Level of TGF-β1 in BAL fluid. (C) Level of TGF-β1 and Th2 cytokines in lung homogenate. Cytokines in BAL and lung homogenates was measured by ELISA. Data are presented as means ± SEM obtained from 3 different experiments. 3–5 mice per group were used in each experiment (N = 9–14). White bars: PBS-challenged mice in each groups. Black bar: Dp challenged WT mice. Shaded bar: Dp challenged SP-D−/− mice. *p < 0.05.
macrophages in BALF were significantly increased in Dp-challenged SP-D−/− mice when compared to Dp-challenged WT mice, (Figure 3A).

TGF-β1 is recognized to be a key cytokine driving fibrotic lung disease [16]. Total TGF-β1 concentration in BALF of Dp challenged SP-D−/− mice was significantly increased when compared to Dp-challenged WT mice and PBS challenged SP-D−/− mice (Figure 3B). Active TGF-β1 of lung homogenate in Dp challenged SP-D−/− mice tended to increase when compared to Dp-challenged WT mice although there are no statistically significant differences observed (Figure 3C). These findings suggest that functional TGF-β1 was produced around inflammatory site of lung in SP-D deficient mice.

Several Th2 cytokines, IL-4, IL-5 and IL-13, were undetectable in BALF, but were present in the lung homogenates. While there were no detectable differences in IL-4 and IL-5 between both groups of Dp-challenged mice, SP-D−/− mice had significantly increased IL-13 production when compared to WT after Dp-challenge (Figure 3C).

To determine whether Th lymphocytes affected IL-13 production in SP-D−/− mice, we examined the intracellular cytokine profile of Th2/Th1 cells that were present in the total CD4+ cell population (CD3+/CD4+) from the homogenized and digested lung tissue by flow cytometry (Figure 4A). Although, the percentage of IL-4+ T cells trended towards an increase by Dp exposure when compared with PBS challenged mice, there were no detectible differences in percentage of IL-4+ T cells between either group of Dp-challenged mice (Figure 4B). Additionally, there were no detectible differences in the number of IFN-γ+ T cells from lung tissue between all groups of mice (Figure 4C). To determine Th2/Th1 cytokine production per T cells basis, we analyzed mean fluorescence intensity (MFI) of IL-4 and IFN-γ per cell basis. MFI of IL-4 in Dp challenged SP-D−/− mice was only slightly increased compared to PBS challenged SP-D−/− mice, and appears to be within 2 fold increase compared to Dp challenged WT mice (Figure 4D). There were no detectible differences in MFI of IFN-γ
between all groups of mice (Figure 4E). Based on these results, we did not observe detectible differences in Th2/Th1 lymphocyte populations and Th2/Th1 cytokines in SP-D−/− mice, which suggests that Th2/Th1 lymphocytes may not be a major contributor to the SP-D-dependent IL-13 production.

**Treatment with exogenous SP-D in Dp-challenged mice**

To determine whether loss of SP-D directly affected the increase of sub-epithelial fibrosis, exogenous SP-D was administrated oropharyngeally into SP-D−/− mice (SP-D rescue treatment mice, SP-D−/− Res). Again, we observed that sub-epithelial fibrosis in SP-D−/− mice was increased by chronic Dp exposure as compared to WT Dp exposed mice. However, in Dp-challenged SP-D−/− mice given the SP-D rescue treatment, sub-epithelial fibrosis was attenuated (Figure 5A). Similarly, the thickness of sub-epithelial fibrosis surrounding the bronchus was significantly reduced in Dp-challenged SP-D−/− mice given SP-D rescue treatment when compared to Dp-challenged SP-D−/− mice given vehicle control (Figure 5B). The concentration of collagen in the lungs of Dp challenged SP-D−/− mice was significantly increased compared to that of Dp-challenged WT mice. SP-D rescue treatment also significantly decreased collagen concentration in lungs of Dp-challenge SP-D−/− mice (Figure 5C). Moreover, SP-D rescue treatment also significantly decreased the cellular inflammation (Figure 6A) and total TGF-β1 of BALF (Figure 6B) of Dp-challenged SP-D−/− mice as compared to vehicle treated controls. We observed similar patterns that the increases of both active TGF-β1 and IL-13 in SP-D−/− were reduced by SP-D rescue treatment (Figure 6C and D).

![Figure 5 Sub-epithelial fibrosis in Dp-challenged mice with treatment of exogenous SP-D.](image)
TGF-β1 and IL-13 positive eosinophil infiltration in lungs of Dp-challenged mice

Previous reports have shown that allergic inflammation, including eosinophilia, is related to the establishment of airway remodeling [26,27]. In our studies, histological examination with Luna modified stain demonstrated that peribronchiolar eosinophils (red in cytoplasm) were present in all groups of Dp-challenge mice when compared to PBS-challenged mice (Figure 7A). However, the number of tissue eosinophils was increased in Dp-challenged SP-D−/− mice when compared to Dp-challenged WT mice (Figure 7B). SP-D rescue treatment also significantly decreased the eosinophil infiltration into the tissue of Dp-challenged SP-D−/− mice (Figure 7B). In order to determine if eosinophils are the source of TGF-β1 and IL-13 in Dp-challenged mice, we performed Luna-modified stain and immunohistochemistry using sequential staining techniques. Using this techniques, we are able to show that many of the infiltrated eosinophils which are positive for Luna-modified stain, are also positive for TGF-β1 (blue arrows) and for IL-13 (red arrows) (Figure 7A). As shown in Table 1, while the percentage of TGF-β1 positive and IL-13 positive eosinophils was similar among the groups, the total number of TGF-β1 positive and IL-13 positive eosinophils was significantly increased in SP-D−/− mice compared to WT and SP-D−/− rescue mice. Interestingly, bronchial epithelial cells were also positive for TGF-β1 (Figure 7A). Since the percentage of TGF-β1 positive epithelial cells was not increased in SP-D−/− mice (Table 1), this suggests that epithelium derived TGF-β1 may not be affected by SP-D in this model. These findings further support the notion that eosinophils are an important source of both TGF-β1 and IL-13 and may be regulated by SP-D.

SP-D regulates eosinophil-derived TGF-β1 and IL-13

To determine if SP-D directly regulates eosinophil function, in vitro experiments were performed with purified eosinophils that were stimulated with Dp in the presence or absence of SP-D. Dp-stimulation significantly increased TGF-β1 production from eosinophils in a dose dependent manner (Figure 8A). Interestingly, SP-D pre-treatment of eosinophils significantly reduced TGF-β1 production at both 2 μg/ml and 5 μg/ml doses (Figure 8A). Heat-inactivated SP-D is less effective in inhibiting TGF-β production from eosinophils when compared to multimeric SP-D (Figure 8B). In addition, IL-13 production by isolated eosinophils was also significantly increased by Dp stimulation in a dose dependent manner, which was significantly reduced by SP-D co-incubation (Figure 8B). Taken together, these results demonstrate that SP-D can
directly attenuate Dp-induced eosinophil-derived TGF-β and IL-13 production.

TGF-β blockade inhibits sub-epithelial fibrosis in the SP-D deficient animal

In order to determine whether TGF-β affected sub-epithelial fibrosis in the SP-D−/− mice, we blocked TGF-β1 in our Dp model. Treatment with TGF-β blocking antibody significantly reduced total and active TGF-β1 concentrations as measured in the BALF and whole lung homogenate (Figure 9A). TGF-β1 blockade reduced sub-epithelial fibrosis in both strain of Dp-challenge mice compared to Dp-challenge mice given the IgG isotype control administration (Figure 9B). Additionally, the thickness of sub-epithelial fibrosis in Dp challenged SP-D−/− mice with TGF-β1 Ab treatment was significantly reduced compared to Dp-challenged SP-D−/− mice given the IgG isotype control treatment (Figure 9C). The inhibitory effect of anti-TGF-β treatment in SPD−/− mice was higher than that in WT mice (WT vs SP-D−/−; 31.7% reduced vs 50.0% reduced, respectively) (Figure 9C). Collagen concentrations were also significantly decreased in SP-D−/− Dp challenged lungs that had been given TGF-β1 Ab treatment when compared to those given IgG isotype control treatment (Figure 9D). Interestingly, TGF-β1 Ab treatment significantly decreased IL-13 concentration in SPD−/− mice, although it was not effective for WT mice (Figure 9E). These results support that TGF-β1 is key cytokine in establishing Dp-induced sub-epithelial fibrosis in mice that lack functional SP-D.

Discussion

Sub-epithelial fibrosis is a major complication of chronic allergic airways disease and can result in fixed air-flow

Table 1 Histological data of eosinophils and epithelial cells by IHC

| TGF+ Eo (No./mm) | % of TGF+ Eo (%) | IL13+ Eo (No./mm) | % of IL13+ Eo (%) | % of TGF+ epithelial cells (%) |
|------------------|-----------------|------------------|------------------|-------------------------------|
| WT Dp/Dp         | 7.67 ± 1.90     | 42.34 ± 3.71     | 8.41 ± 1.79      | 41.83 ± 3.87                  | 88.35 ± 5.14                  |
| SPD−/− Dp/Dp     | 14.51 ± 1.92*   | 41.91 ± 3.90     | 15.32 ± 2.59†    | 41.58 ± 4.31                  | 91.65 ± 3.68                  |
| SPD−/− rescue Dp/Dp | 9.06 ± 1.45†   | 40.38 ± 4.29     | 8.65 ± 1.32†     | 37.34 ± 2.43                  | 97.07 ± 1.31                  |

TGF-β1 and IL-13 were stained by immunohistochemistry (IHC). Methods to evaluate the IHC stain were described in Material and Methods. Data are presented as means ± SEM obtained from 3 different experiments. 3–5 mice per group were used in each experiment (N = 7-11). Eo: eosinophils. Dp/Dp: Dp-sensitized and Dp-challenged mice. *: P < 0.05 compared with WT mice. †: P < 0.05 compared with SPD−/− mice.
obstruction. Current understanding of the fundamental molecular mechanisms resulting in sub-epithelial fibrosis and effective therapeutic interventions remains limited. Utilizing a mouse model of chronic challenge to clinically relevant house dust mite, we demonstrate a central role of SP-D in the development of sub-epithelial fibrosis. Our new findings support that SP-D regulates the number of tissue eosinophils and the level of eosinophil-derived TGF-β1 and IL-13. Together our findings provide novel evidence supporting that functional SP-D can protect allergic airways from the development of sub-epithelial fibrosis.

TGF-β is known as a key cytokine of collagen production in fibrotic disease including airway remodeling in asthma [16,21]. TGF-β can induce differentiation of fibroblasts to myofibroblasts, which can contribute to collagen deposition [28] and production of growth factors [29,30]. Previous reports demonstrated anti TGF-β1 or smad3 neutralizing antibody treatment reduced airway remodeling in OVA chronic exposure model [31,32]. In our findings, TGF-β1 production was increased in SP-D−/− mice, contributing to enhanced sub-epithelial fibrosis. Interestingly, SP-D can bind to allergens including Dp [6]. Therefore, if functional SP-D is absent, unbound Dp antigen may be a trigger that leads to enhanced TGF-β1 production and sub-epithelial fibrosis as observed in SP-D−/− mice.

Previous work has suggested that sub-epithelial fibrosis after chronic challenge to house dust mite antigen was independent of either eosinophils or TGF-β1 [33,34]. In that context, our observation that anti-TGF-β1 antibody treatment reduced sub-epithelial fibrosis and collagen production in the Dp-challenged SP-D deficient mice was quite unexpected. One explanation is that the previous studies used mice that were sufficient in SP-D and the involvement of eosinophils and/or

![Figure 8 SP-D regulates eosinophil-derived TGF-β1 and IL-13](image-url)
TGF-β1 may not be appreciated until SP-D is absent or dysfunctional. Alternatively, IL-13 is recognized as a Th2 cytokine that can contribute to sub-epithelial fibrosis and a pro-fibrotic cytokine in lung diseases [35]. IL-13 depletion can reduce sub-epithelial fibrosis and epithelial hypertrophy in chronic asthma model [36,37]. Fattouh et al. demonstrated that IL-13 was important for airway fibrosis independent of TGF-β signaling in Th2 associated disease [34,38]. Our findings demonstrate that IL-13 production was increased in Dp-challenged SP-D−/− mice and SP-D rescue decrease these responses similar to previous observations [34]. In addition, our findings demonstrate that anti-TGF-β1 antibody treatment decreased IL-13 production in lung homogenate in SP-D−/− mice (Figure 9), which suggests a potential synergistic role between TGF-β1 and IL-13 in airway remodeling when SP-D is absent. A previous study found that administration of a soluble TGF-β receptor-Fc molecule ameliorated IL-13-induced fibrosis [39], supporting this paradigm. Recent reports also showed that inhibition of TGF-β1/smad3 signaling can lead to decrease IL-13 production in lung diseases [40,41]. Similar mechanism seems to occur in the lung of SP-D−/− mice, which warrant further study.

In either chronic antigen exposure asthma model or gene-modified model, both peribronchial fibrosis and TGF-β production were related to eosinophils [26,27]. In airways of asthmatic patients, 75-80% of TGF-β1 mRNA expression positive cells were eosinophils [42,43]. On the other hand, it is known that bronchial epithelial cells were also source of TGF-β1 in asthma [44]. In OVA challenged model, bronchial epithelium-derived TGF-β1 was enhanced sub-epithelial fibrosis [31]. Therefore, we examined what type of cells that are a potential source of TGF-β1 and as target cells by SP-D in this model. In the present findings, TGF-β1 expressing eosinophils were increased in Dp-challenged SP-D−/− mice. Moreover, we identified that SP-D directly suppress the production of eosinophil derived TGF-β. To our knowledge, this is the first report to demonstrate a direct function of SP-D on eosinophils response to antigen. In contrast, our findings showed that TGF-β1 expression in bronchial epithelial cells of SP-D−/− mice were not significant difference among the 3 groups unlike TGF expression in eosinopils (Figure 7 and Table 1). Based on these results, our findings suggest that a target of SP-D in Dp-induced sub-epithelial fibrosis may be the activated eosinophils that produce TGF-β1. In addition to
regulation of eosinophil-derived TGF-β, SP-D also attenuated IL-13 production from Dp stimulated eosinophils. Since we did not identify an increase Th2 cells in the lung tissue from SP-D−/− mice, our findings suggest that eosinophils may be also an important source of IL-13 as reported in other model systems [45]. Taken together, our findings support that functional SP-D regulates both the tissue infiltration and function of eosinophils, resulting in protection of the airways against development of sub-epithelial fibrosis. Our findings extend the functional role of SP-D in allergic airways disease beyond regulation of eosinophil-derived cytokines and degranulation of eosinophils [46], induction of apoptosis in eosinophils, and enhanced uptake of eosinophils by macrophages [47].

The molecular mechanism that SP-D inhibited TGF-β1 and IL-13 production by Dp-activated eosinophils also remains unknown. Previous reports have shown that interstitial eosinophils express high levels of signal regulatory protein (SIRP)-α, an inhibitory receptor of SP-D, and that cross-linking of SIRP-α on the surface of eosinophils significantly reduced the amount of eosinophil peroxidase released during stimulation with a calcium ionophore [48]. In macrophages under normal condition, SP-D binds SIRP-α, leading to inhibit p38 activation, which induces cytokine production via Src homology region 2 domain-containing phosphatase (SHP)-1 [49,50]. It remains unknown whether similar events occur in eosinophils during chronic allergic inflammatory conditions. Since Toll-like receptor (TLR) 4 is candidate of receptor of Dp [51], it is possible that SP-D bind Dp directly in order to block Dp binding to TLR4. Alternatively, SP-D may also interfere with signaling by binding directly to TLR4. Understanding the molecular mechanisms that SP-D regulates eosinophil function will be the focus of future investigations.

In conclusion, we identify that SP-D regulates eosinophil production of both IL-13 and TGF-β after stimulation with Dp, mitigating sub-epithelial fibrosis which is an important component of airway remodeling in chronic allergic airways disease. Appreciation of the functional role of SP-D during allergic airways disease is high clinical significance since a better understanding of how to attenuate the severity of sub-epithelial fibrosis could lead to better treatment options.

Additional file

Additional file 1: Surfactant Protein D Attenuates Sub-epithelial Fibrosis through Regulation of Eosinophil-derived TGF-β in Chronic Murine Model of Asthma.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

HO, JGL, SM and JWH contributed conception, study design, data interpretation, and writing of the manuscript. HO, JGL, and SM carried out acquisitions of data. HO, JGL, SM and YA carried out analysis and interpretation. HO and NI carried out histopathology and IHC. JIL and YN participated in experimental design and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgement

We thank the late Dr. Jo Rae Wright for providing the opportunity to study airway remodeling using SP-D−/− mice and for her intellectual contribution during the initial conception of this project. We appreciate Dr. Jeffrey Whitsett for providing the SP-D deficient mice used in this study. We also thank Katherine Evans (Duke University) for the preparation of recombinant rat SP-D. Charles Giambardino (Duke University) and Julia L. Nugent (Duke University) for the technical support. We thank Mrs Megumi Kume and Miss Hitomi Umemoto (Department of Molecular and Environmental Pathology, Institute of Health Biosciences, the University of Tokushima Graduate School) for preparing histological sections and stains. We appreciate the continued support provided by the NIH (ES016126, AI081672, ES020350, HL111151).

Author details

1Department of Cell Biology, Duke University Medical Center, Durham, North Carolina, USA. 2Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA. 3Department of Respiratory Medicine and Rheumatology, Institute of Health Bioscience, University of Tokushima Graduate School, Tokushima, Japan. 4Department of Molecular and Environmental Pathology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan. 5Department of Biochemistry and Molecular Biology, Division of Pulmonary Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA. 6Department of Medicine, Wexner Medical Center at Ohio State University, Columbus, Ohio, USA. 7Davis Heart & Lung Research Institute at Ohio State University, 473 West 12th Avenue, Columbus, OH, USA.

Received: 7 April 2014 Accepted: 1 November 2014

Published online: 29 November 2014

References

1. Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 2005, 5:58–68.
2. Giannori E, Sawo T, Allen L, Wiener-Kronish J, Hawgood S: Surfactant proteins A and D enhance pulmonary clearance of Pseudomonas aeruginosa. Am J Respir Cell Mol Biol 2006, 34:704–710.
3. Olek I, Meska A, Kalina M, Fensei Y, Podoschin R, Sahly H, Chang D, McGieger D, Crouch E: Surfactant protein D enhances phagocytosis and killing of unencapsulated phase variants of Klebsiella pneumoniae. Infect Immun 2001, 69:24–33.
4. LeVine AM, Elliott J, Whitsett JA, Srikritthchorn A, Crouch E, DeSilva N, Korfhagen TR: Surfactant protein-D enhances phagocytosis and pulmonary clearance of respiratory syncytial virus. Am J Respir Cell Mol Biol 2004, 31:193–199.
5. LeVine AM, Whitsett JA, Hartshorn KL, Crouch EC, Korfhagen TR: Surfactant protein D enhances clearance of influenza A virus from the lung in vivo. J Immunol 2001, 167:5868–5873.
6. Wang JT, Kishore U, Lim BL, Strong P, Reid KMB: Interaction of human lung surfactant proteins A and D with mite (Dermatophagoides pteronyssinus) allergens. Clin Exp Immunol 1996, 106:367–373.
7. Allen MJ, Harbeck R, Smith B, Voelker DR, Mason RJ: Binding of rat and human surfactant proteins A and D to Aspergillus fumigatus conidia. Infect Immun 1999, 67:4563–4569.
8. Erpenbeck VJ, Malherbe DC, Sommer S, Schmielau A, Steinhielker W, Ghio AJ, Krug N, Wright JR, Hofheidel JM: Surfactant protein D increases phagocytosis and aggregation of pollen-allergen starch granules. Am J Physiol Lung Cell Mol Physiol 2005, 288:L692–L698.
9. Takeda K, Miyahara N, Rha YH, Taube C, Yang ES, Joetham A, Kodama T, Balhorn AM, Dakharma A, Duce C, Evans AJ, Voelker DR, Gefand EW: Surfactant protein D regulates airway function and allergic inflammation through modulation of macrophage function. Am J Respir Crit Care Med 2003, 168:783–789.
10. Erpenbeck VJ, Ziegert M, Cavalet-Blanco D, Martin C, Baelder R, Glaab T, Braun A, Steinhalber W, Luettg B, Uhlig S, Hoymann HG, Krug N, Hoříček JM: Surfactant protein D inhibits early airway response in Aspergillus fumigatus-sensitized mice. Clin Exp Allergy 2006, 36:930–940.

11. Liu CF, Chen YL, Sheen CC, Yu CH, Reid KMB, Wang JT: Therapeutic effect of surfactant protein D in allergic inflammation of mite-sensitized mice. Clin Exp Allergy 2005, 35:615–521.

12. Singh M, Madan T, Waters P, Parida SK, Sarma PU, Kishore U: Protective effects of a recombinant fragment of human surfactant protein D in a murine model of pulmonary hypersensitivity induced by dust mite allergens. Immunol Lett 2003, 86:299–307.

13. Strong P, Townsend P, Mackay R, Reid KB, Clark HW: A recombinant fragment of human SP-D reduces allergic responses in mice sensitized to house dust mite allergens. Clin Exp Immunol 2003, 134:181–187.

14. Casey J, Kaplan J, Atrachina-Vassemann EN, Gow AJ, Keddie H, Tomer Y, Fisher JH, Havgood S, Savani RC, Beers MF: Alveolar surfactant protein D content modulates bleomycin-induced lung injury. Am J Respir Crit Care Med 2003, 167:269–277.

15. Goto H, Ledford JG, Mukherjee S, Noble PW, Williams KL, Wright JR: The role of surfactant protein A in bleomycin-induced acute lung injury. Am J Respir Crit Care Med 2010, 181:1336–1344.

16. Aono Y, Ledford JG, Mukherjee S, Ogawa H, Nishikawa Y, Sone S, Beers MF, Noble PW, Wright JR: Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. Am J Respir Crit Care Med 2012, 185:523–536.

17. Barlo NP, van Myoore CHM, Raven HHT, Zanen P, van den Bosch JMM, Grutters JC: Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis. Respir Care 2009, 54:1557–1563.

18. Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, King JH, Hawgood S, Savani RC, Beers MF: Surfactant protein-A regulates lung inflammation and fibrotic lung remodeling in a murine model of pulmonary hypersensitivity induced by dust mite allergens. J Immunol 2009, 182:2074–2081.

19. Lee NA, McGarry MP, Larson KA, Horton MA, Kristensen AB, Lee JJ: Recombinant surfactant protein-D suppresses bleomycin-induced lung injury and fibrotic lung remodeling in mice. J Appl Physiol 2011, 110:2070–2078.

20. Wert SE, Yoshida M, LeVine AM, Ikegami M, Jones T, Ross GF, Fisher JH, Nimz AJ, Humbles AA, Jordana M: Transforming growth factor-beta regulates house dust mite-induced allergic airway inflammation but not airway remodeling. Am J Respir Crit Care Med 2011, 183:179–188.

21. Alcorn JR, Rinaldi LM, Jaffe EF, van Loon M, Bates JH, Jansen-Heninger YM, Irvin CG: Transforming growth factor-beta1 suppresses airway hyperresponsiveness in allergic airway disease. Am J Respir Crit Care Med 2007, 176:974–982.

22. McMillan SJ, Xanthou G, Lloyd CM: Manipulation of allergen-induced airway remodeling by treatment with anti-TGF-beta antibody: effect on the Smad signaling pathway. J Immunol 2005, 174:5774–5780.

23. Fattouh R, Al-Garawi A, Fattouh M, Arias K, Walker TD, Goncharova S, Coyle AJ, Humbles AA, Jordan D: Eosinophils are dispensable for allergic remodeling and immunity in a model of house dust mite-induced airway disease. Am J Respir Crit Care Med 2011, 183:179–188.

24. Pasula R, Wright JR, Kachel DL, Martin WJ 2nd: Surfactant protein protein A suppresses reactive nitrogen intermediates by alveolar macrophages in response to Mycobacterium tuberculosis. J Clin Invest 1999, 103:463–490.

25. Ogawa H, Azuma M, Muto S, Nishikawa Y, Honjo A, Tezuka T, Uehara H, Iizumi K, Itai A, Sone S: An kappa B kinase inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus-sensitized mouse model of chronic asthma. Am J Physiol Lung Cell Mol Physiol 2013, 304:L787–L798.

26. Cho JY, Miller MA, Baek KJ, Han JW, Nayar J, Lee SY, McElwain K, McElwain S, Friedman S, Breide DH: Inhibition of airway remodeling in IL-5-deficient mice. J Clin Investig 2004, 113:511–520.

27. Ochkur SI, Jacobsen EA, Protheroe CA, Biechele TL, Pero RS, McGarry MP, Ehlers C, Schalch J, Christenson DR, Donaldson K: Expression of IL-5 in thymocytes/T cells leads to the development of a massive eosinophilia, extramedullary eosinophilopoiesis, and unique characteristics of severe asthma. J Immunol 2005, 174:1584–1594.

28. Thomas PW, Kishore U, Sarma PU: Expression of IL-5 in thymocytes/T cells leads to the development of a massive eosinophilia, extramedullary eosinophilopoiesis, and unique characteristics of severe asthma. J Immunol 2005, 174:1584–1594.

29. Khalil N, Xu YD, O'Connor R, Duronio V: Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-beta 1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK. J Biol Chem 2005, 280:4300–43009.

30. Utsugi M, Dobashi K, Ishizuka T, Masubuchi K, Shirazui Y, Nakazawa T, Mor O: Ceramide-1-H2-terminal kinase mediates expression of connective tissue growth factor induced by transforming growth factor-beta1 in human lung fibroblasts. Am J Respir Cell Mol Biol 2003, 28:754–761.

31. Alcorn JR, Rinaldi LM, Jaffe EF, van Loon M, Bates JH, Jansen-Heninger YM, Irvin CG: Transforming growth factor-beta1 suppresses airway hyperresponsiveness in allergic airway disease. Am J Respir Crit Care Med 2007, 176:974–982.

32. McMillan SJ, Xanthou G, Lloyd CM: Manipulation of allergen-induced airway remodeling by treatment with anti-TGF-beta antibody: effect on the Smad signaling pathway. J Immunol 2005, 174:5774–5780.

33. Fattouh R, Al-Garawi A, Fattouh M, Arias K, Walker TD, Goncharova S, Coyle AJ, Humbles AA, Jordan D: Eosinophils are dispensable for allergic remodeling and immunity in a model of house dust mite-induced airway disease. Am J Respir Crit Care Med 2011, 183:179–188.

34. Pasula R, Wright JR, Kachel DL, Martin WJ 2nd: Surfactant protein protein A suppresses reactive nitrogen intermediates by alveolar macrophages in response to Mycobacterium tuberculosis. J Clin Investig 1999, 103:463–490.

35. Ogawa H, Azuma M, Uehara H, Takahashi T, Nishikawa Y, Sone S, Iizumi K, Nerve growth factor derived from bronchial epithelium after chronic mite antigen exposure contributes to airway hyperresponsiveness by inducing interneurin, and is inhibited by in vivo siRNA. Clin Exp Allergy 2012, 42:460–70.

36. Cho JY, Miller MA, Baek KJ, Han JW, Nayar J, Lee SY, McElwain K, McElwain S, Friedman S, Breide DH: Inhibition of airway remodeling in IL-5-deficient mice. J Clin Investig 2004, 113:511–520.

37. Ochkur SI, Jacobsen EA, Protheroe CA, Biechele TL, Pero RS, McGarry MP, Wang HY, O'Neill KR, Colbert DC, Colby TV, Shen HH, Blackburn MR, Irvin CC, Lee JJ, Lee NA: Coexpression of IL-5 and eotaxin-2 in mice creates an eosinophilic-dependent model of respiratory inflammation with characteristics of severe asthma. J Immunol 2007, 178:7697–7698.

38. Hashimoto S, Ono Y, Takehisa J, Matsumoto K, Maruoka S, Horie T: Transforming growth factor-beta1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-jun-NH2-terminal kinase-dependent pathway. Am J Respir Crit Care Med 2001, 163:152–157.

39. Khalil N, Xu YD, O’Connor R, Duronio V: Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-beta 1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK. J Biol Chem 2005, 280:4300–43009.
49. Gardai SJ, Xiao YQ, Dickinson M, Nick JA, Voelker DR, Greene KE, Henson PM: By binding SIRP alpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 2003, 115:13–23.

50. Janssen WJ, McPhillips KA, Dickinson MG, Linderman DJ, Morimoto K, Xiao YQ, Oldham KM, Vandivier RW, Henson PM, Gardai SJ: Surfactant proteins A and D suppress alveolar macrophage phagocytosis via interaction with SIRP alpha. Am J Respir Crit Care Med 2008, 178:158–167.

51. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN: House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med 2009, 15:410–416.

doi:10.1186/s12931-014-0143-9

Cite this article as: Ogawa et al.: Surfactant protein D attenuates subepithelial fibrosis in allergic airways disease through TGF-β. Respiratory Research 2014 15:143.